Mottaghi Peyman
Assistant Professor, Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail:
J Res Med Sci. 2010 May;15(3):175-84.
Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women. These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density.This article proposed to review effectiveness and tolerability of intravenous BPs in postmenopausal women with osteoporosis.
大量临床研究表明，双膦酸盐（BPs）是预防骨折和绝经后骨质流失的有效且具成本效益的选择。口服双膦酸盐的使用是绝经后女性骨质疏松症管理的既定选择，但许多患者抱怨有胃肠道副作用或口服给药方案频繁。为改善绝经后女性治疗依从性欠佳的情况，新型、长效静脉用双膦酸盐制剂已获批用于绝经后女性的间歇性给药。这些制剂将成为无法耐受口服双膦酸盐或其在增加骨密度方面无效的患者的一种选择。本文旨在综述静脉用双膦酸盐在绝经后骨质疏松症女性中的有效性和耐受性。
